376 related articles for article (PubMed ID: 31894377)
1. Real-world outcomes following 12 months of intravitreal aflibercept monotherapy in patients with diabetic macular edema in France: results from the APOLLON study.
Korobelnik JF; Daien V; Faure C; Tadayoni R; Giocanti-Auregan A; Dot C; Kodjikian L; Massin P
Graefes Arch Clin Exp Ophthalmol; 2020 Mar; 258(3):521-528. PubMed ID: 31894377
[TBL] [Abstract][Full Text] [Related]
2. Two-year outcomes of the APOLLON observational study of intravitreal aflibercept monotherapy in France in patients with diabetic macular edema.
Korobelnik JF; Daien V; Faure C; Tadayoni R; Giocanti-Aurégan A; Dot C; Kodjikian L; Massin P;
Sci Rep; 2022 Oct; 12(1):18242. PubMed ID: 36309572
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal aflibercept for diabetic macular edema in real-world clinical practice in Japan: 24-month outcomes.
Sugimoto M; Handa C; Hirano K; Sunaya T; Kondo M
Graefes Arch Clin Exp Ophthalmol; 2022 Nov; 260(11):3489-3498. PubMed ID: 35652946
[TBL] [Abstract][Full Text] [Related]
4. Suprachoroidal CLS-TA plus Intravitreal Aflibercept for Diabetic Macular Edema: A Randomized, Double-Masked, Parallel-Design, Controlled Study.
Barakat MR; Wykoff CC; Gonzalez V; Hu A; Marcus D; Zavaleta E; Ciulla TA
Ophthalmol Retina; 2021 Jan; 5(1):60-70. PubMed ID: 32829027
[TBL] [Abstract][Full Text] [Related]
5. Impact of intravitreal aflibercept dosing regimens in treatment-naïve patients with neovascular age-related macular degeneration: 2-year results of RAINBOW.
Weber M; Dominguez M; Coscas F; Faure C; Baillif S; Kodjikian L; Cohen SY
BMC Ophthalmol; 2020 May; 20(1):206. PubMed ID: 32450838
[TBL] [Abstract][Full Text] [Related]
6. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.
Bahrami B; Hong T; Zhu M; Schlub TE; Chang A
Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1133-1140. PubMed ID: 28238195
[TBL] [Abstract][Full Text] [Related]
7. COMPARISON OF INTRAVITREAL DEXAMETHASONE IMPLANT AND AFLIBERCEPT IN PATIENTS WITH TREATMENT-NAIVE DIABETIC MACULAR EDEMA WITH SEROUS RETINAL DETACHMENT.
Ozsaygili C; Duru N
Retina; 2020 Jun; 40(6):1044-1052. PubMed ID: 30950970
[TBL] [Abstract][Full Text] [Related]
8. One-Year Results of Using a Treat-and-Extend Regimen without a Loading Phase with Anti-VEGF Agents in Patients with Treatment-Naive Diabetic Macular Edema.
Schwarzer P; Ebneter A; Munk M; Wolf S; Zinkernagel MS
Ophthalmologica; 2019; 241(4):220-225. PubMed ID: 30654365
[TBL] [Abstract][Full Text] [Related]
9. Vision-Related Quality of Life in Patients with Diabetic Macular Edema Treated with Intravitreal Aflibercept: The AQUA Study.
Garweg JG; Stefanickova J; Hoyng C; Schmelter T; Niesen T; Sowade O; Sivaprasad S;
Ophthalmol Retina; 2019 Jul; 3(7):567-575. PubMed ID: 31080168
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of standard of care intravitreal aflibercept treatment of diabetic macular oedema treatment-naive patients in the UK: DRAKO study 12-month outcomes.
Sivaprasad S; Ghanchi F; Kelly SP; Kotagiri A; Talks J; Scanlon P; McGoey H; Nolan A; Saddiq M; Napier J;
Eye (Lond); 2022 Jan; 36(1):64-71. PubMed ID: 34244670
[TBL] [Abstract][Full Text] [Related]
11. Final 4-year results of the RAINBOW real-world study: intravitreal aflibercept dosing regimens in France in treatment-naïve patients with neovascular age-related macular degeneration.
Cohen SY; Dominguez M; Coscas F; Faure C; Baillif S; Oubraham H; Kodjikian L; Weber M;
Graefes Arch Clin Exp Ophthalmol; 2023 Apr; 261(4):959-969. PubMed ID: 36399178
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of care with intravitreal aflibercept treatment for UK patients with diabetic macular oedema: DRAKO study 24-month real-world outcomes.
Sivaprasad S; Ghanchi F; Kelly SP; Kotagiri A; Talks J; Scanlon P; McGoey H; Nolan A; Saddiq M; Napier J
Eye (Lond); 2023 Sep; 37(13):2753-2760. PubMed ID: 36941402
[TBL] [Abstract][Full Text] [Related]
13. EFFECT OF BASELINE CENTRAL RETINAL THICKNESS ON THE RESULTS OF TREATMENT OF DIABETIC MACULAR EDEMA WITH AFLIBERCEPT: REAL-LIFE EVIDENCE IN THE CZECH REPUBLIC.
Němčanský J; Stepanov A; Veith M; Koubek M; Kopecký A; Němčanská S; Beran D; Studnička J
Cesk Slov Oftalmol; 2022; 78(2):64-70. PubMed ID: 35477246
[TBL] [Abstract][Full Text] [Related]
14. Dosing Regimens of Intravitreal Aflibercept for Diabetic Macular Edema Beyond the First Year: VIOLET, a Prospective Randomized Trial.
Garweg JG; Štefanickova J; Hoyng C; Niesen T; Schmelter T; Leal S; Sivaprasad S;
Adv Ther; 2022 Jun; 39(6):2701-2716. PubMed ID: 35412227
[TBL] [Abstract][Full Text] [Related]
15. Systematic review and mixed treatment comparison of intravitreal aflibercept with other therapies for diabetic macular edema (DME).
Korobelnik JF; Kleijnen J; Lang SH; Birnie R; Leadley RM; Misso K; Worthy G; Muston D; Do DV
BMC Ophthalmol; 2015 May; 15():52. PubMed ID: 25975823
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration.
Razavi S; Kodjikian L; Giocanti-Aurégan A; Dufour I; Souied E
BMC Ophthalmol; 2021 Feb; 21(1):90. PubMed ID: 33596867
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal Aflibercept for the Treatment of Diabetic Macular Edema in Routine Clinical Practice: Results from the 24-Month AURIGA Observational Study.
Donati S; Yang CH; Xu X; Mura M; Giocanti-Aurégan A; Hoerauf H; Allmeier H; Machewitz T; Johnson KT; Santoro E;
Ophthalmol Ther; 2024 Jan; 13(1):161-178. PubMed ID: 37924483
[TBL] [Abstract][Full Text] [Related]
18. INVICTUS: Intravitreal anti-VEGF and dexamethasone implant comparison for the treatment of diabetic macular edema: A 12 months follow-up study.
Comet A; Gascon P; Ramtohul P; Donnadieu B; Denis D; Matonti F
Eur J Ophthalmol; 2021 Mar; 31(2):754-758. PubMed ID: 32507032
[TBL] [Abstract][Full Text] [Related]
19. AFLIBERCEPT FOR PERSISTENT DIABETIC MACULAR EDEMA: Forty-Eight-Week Outcomes.
Bahrami B; Hong T; Schlub TE; Chang AA
Retina; 2019 Jan; 39(1):61-68. PubMed ID: 30015767
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti-Vascular Endothelial Growth Factor Treatment: Outcomes from the Phase 3 Program.
Do DV; Nguyen QD; Vitti R; Berliner AJ; Gibson A; Saroj N; Soo Y; Boyer DS
Ophthalmology; 2016 Apr; 123(4):850-7. PubMed ID: 26832658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
